Jury rules Prempro caused woman’s breast cancer

Share this article:
A Philadelphia jury found on Tuesday that Wyeth’s hormone replacement therapy Prempro was the cause of a woman’s breast cancer and awarded her and her husband damages of $3 million. Wyeth said it plans to appeal the decision. “We respectfully disagree that there is any scientific basis to support the jury’s finding of a causal link between Wyeth’s hormone therapies and the plaintiff’s breast cancer,” said Barbara Binis, an attorney representing Wyeth in the case. A previous Philadelphia jury also found in favor of the plaintiff, Jennie Nelson in October. However the judge threw out that verdict and declared a mistrial, leading to the trial that concluded yesterday. The original jury had awarded Nelson and her husband $1.5 million in compensatory damages. This time Nelson was awarded $2.4 million and her husband $600,000. The reason for the mistrial was not disclosed however there has been speculation since that it may have been overturned as a result of juror misconduct. Wyeth is facing approximately 5,000 lawsuits over its hormone replacement therapies. The drugs remain on the market despite a major government-sponsored study that found using them for five years or more can increase the risk of breast cancer.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.